Clinical Trial Update: Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820 [Phase 4]

View source ↗

Summary

A Phase 4 roll-over trial evaluating idelalisib for participants previously treated with GS-9820 (another PI3Kδ inhibitor) has been terminated; results posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoid Malignancies

Drugs mentioned

• Idelalisib (idelalisib)

Snippet

Sponsor: Gilead Sciences | Conditions: Lymphoid Malignancies | Phase 4 | Status: TERMINATED | Results posted: 2019-01-16